Astellas Pharma Inc.: Business Overview, Financials & Competitive Analysis
Astellas Pharma Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Trading at 56.1% below estimate of fair value, but faces long-term revenue headwinds from patent expirations and competitive pressures. The company has shifted back into profit on a trailing twelve month basis with net income of ¥322.9b compared to a loss of ¥57.4b a year ago, supported by three.
What is Astellas Pharma Inc.'s industry? Astellas Pharma Inc. (astellas.com) operates in Pharmaceutical Manufacturing - General. AskCyborg classifies Astellas Pharma Inc. under Pharmaceutical Manufacturing - General in its company registry.
Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company is a specialty international pharmaceutical company focused on accelerating the discovery, dev...
Cyborg Score thesis
Trading at 56.1% below estimate of fair value, but faces long-term revenue headwinds from patent expirations and competitive...
Read the full analyst-debate transcript →Get the Latest Astellas Pharma Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeAstellas Pharma Inc. Overview
Pro stress-test →Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company is a specialty international pharmaceutical company focused on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases.
Strategic Profile
Pro stress-test →The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Astellas is experiencing strong global sales trends of XTANDI for prostate cancer and BETANIS/MYRBETRIQ/BETMIGA for overactive bladder.
Competitive Landscape
Pro stress-test →One of Astellas Pharma's 64 competitors is Novartis, a Corporation company based in Basel, Switzerland. Loss of exclusivity for major drugs and persistent R&D challenges threaten future revenue stability, while pricing pressures, regulatory risks, and supply chain complexities increase margin volatility across key global markets.
Industry Context
Astellas Pharma Inc. operates in Pharmaceutical Manufacturing - General.
Key facts
Founded: 1923 · Headquarters: Chuo, Japan · Revenue: $13.4B · Market cap: $28.9B